Furuta Milano 4

What Happened

• Furuta Milano, Chief Financial Officer of Takeda Pharmaceutical (TAK), had a disposition to the issuer on July 10, 2026 of 16,619 shares (reported as a derivative transaction) for total proceeds of $81,956,599. The weighted-average price reported was JPY 4,931.50 (sales ranged JPY 4,882–5,050).
• On July 1, 2026 Milano was granted awards (reported as acquisitions at $0.00) totaling 25,164 restricted stock units (RSUs): 12,300 RSUs plus three grants of 4,288 RSUs. The RSUs vest in three equal annual installments beginning June 1, 2027.
• Footnotes indicate the July 10 disposition relates to Tax Obligation Awards — economic equivalents of shares that are converted to cash primarily to cover tax obligations; any remaining proceeds were to be delivered to the reporting person on July 10.

Key Details

• Transaction dates: RSU grants on 2026-07-01; disposition to issuer on 2026-07-10.
• Sale details: 16,619 shares disposed; weighted-average price JPY 4,931.50; proceeds $81,956,599. Reported sale prices ranged JPY 4,882–5,050; reporting person can provide a breakdown by price on request (footnote).
• Grants: 25,164 RSUs awarded on 2026-07-01; vest in three equal annual installments beginning 2027-06-01 (footnote F1).
• Nature of transactions: Disposition listed as “Derivative” and described in footnotes as Tax Obligation Awards converted to cash primarily to cover tax liabilities (footnotes F2, F4).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Filing dated 2026-07-06; no indication in the supplied data that this filing was late.

Context

• This filing appears to record standard equity compensation (RSU grants) and a cash settlement/disposition tied to tax withholding (common when RSUs vest). Such tax-related dispositions are routine and do not necessarily indicate a change in insider sentiment.